Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

References for PMC Articles for PubMed (Select 23008748)

1.

Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.

Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB.

Mol Psychiatry. 2012 Jun;17(6):642-9. doi: 10.1038/mp.2011.82. Epub 2011 Jul 12.

2.

Cannabinoids improve driving ability in a Tourette's patient.

Brunnauer A, Segmiller FM, Volkamer T, Laux G, Müller N, Dehning S.

Psychiatry Res. 2011 Dec 30;190(2-3):382. doi: 10.1016/j.psychres.2011.05.033. Epub 2011 Jun 12. No abstract available.

PMID:
21664699
3.

A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction.

Ostenfeld T, Price J, Albanese M, Bullman J, Guillard F, Meyer I, Leeson R, Costantin C, Ziviani L, Nocini PF, Milleri S.

Clin J Pain. 2011 Oct;27(8):668-76. doi: 10.1097/AJP.0b013e318219799a.

PMID:
21540741
4.

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; Sativex Spasticity Study Group.

Eur J Neurol. 2011 Sep;18(9):1122-31. doi: 10.1111/j.1468-1331.2010.03328.x. Epub 2011 Mar 1.

PMID:
21362108
5.

Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial.

Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, MacDonald N, Baracos VE, Wismer WV.

Ann Oncol. 2011 Sep;22(9):2086-93. doi: 10.1093/annonc/mdq727. Epub 2011 Feb 22.

6.

Improvement in refractory psychosis with dronabinol: four case reports.

Schwarcz G, Karajgi B.

J Clin Psychiatry. 2010 Nov;71(11):1552-3. doi: 10.4088/JCP.10l06035yel. No abstract available.

PMID:
21114952
7.

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA.

Pharmacol Rev. 2010 Dec;62(4):588-631. doi: 10.1124/pr.110.003004. Review.

8.

Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.

Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D.

Br J Clin Pharmacol. 2010 Nov;70(5):656-63. doi: 10.1111/j.1365-2125.2010.03743.x.

9.

Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study.

Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM.

Am J Phys Med Rehabil. 2010 Oct;89(10):840-8. doi: 10.1097/PHM.0b013e3181f1c4ec.

PMID:
20855984
10.

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ.

Mult Scler. 2010 Nov;16(11):1349-59. doi: 10.1177/1352458510378020. Epub 2010 Sep 9.

PMID:
20829244
11.

Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study.

Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD, Vosburg SK, Haney M.

Psychopharmacology (Berl). 2010 Dec;212(4):675-86. doi: 10.1007/s00213-010-1995-4. Epub 2010 Sep 8.

12.

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.

Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP.

CMAJ. 2010 Oct 5;182(14):E694-701. doi: 10.1503/cmaj.091414. Epub 2010 Aug 30.

13.

A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury.

Pooyania S, Ethans K, Szturm T, Casey A, Perry D.

Arch Phys Med Rehabil. 2010 May;91(5):703-7. doi: 10.1016/j.apmr.2009.12.025.

PMID:
20434606
14.

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.

Ware MA, Fitzcharles MA, Joseph L, Shir Y.

Anesth Analg. 2010 Feb 1;110(2):604-10. doi: 10.1213/ANE.0b013e3181c76f70. Epub 2009 Dec 10.

PMID:
20007734
15.

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.

Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT.

J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5.

PMID:
19896326
16.

Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.

O'Sullivan SE, Kendall DA.

Immunobiology. 2010 Aug;215(8):611-6. doi: 10.1016/j.imbio.2009.09.007. Epub 2009 Oct 14. Review.

PMID:
19833407
17.
18.

Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.

Centonze D, Mori F, Koch G, Buttari F, Codecà C, Rossi S, Cencioni MT, Bari M, Fiore S, Bernardi G, Battistini L, Maccarrone M.

Neurol Sci. 2009 Dec;30(6):531-4. doi: 10.1007/s10072-009-0136-5. Epub 2009 Sep 19.

PMID:
19768368
19.

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

Schwarcz G, Karajgi B, McCarthy R.

J Clin Psychopharmacol. 2009 Jun;29(3):255-8. doi: 10.1097/JCP.0b013e3181a6bc3b.

PMID:
19440079
20.

Emerging strategies for exploiting cannabinoid receptor agonists as medicines.

Pertwee RG.

Br J Pharmacol. 2009 Feb;156(3):397-411. doi: 10.1111/j.1476-5381.2008.00048.x. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk